Renal Denervation Reduces Monocyte Activation and Monocyte–Platelet Aggregate Formation: An Anti-Inflammatory Effect Relevant for Cardiovascular Risk

Overactivation of renal sympathetic nervous system and low-grade systemic inflammation are common features of hypertension. Renal denervation (RDN) reduces sympathetic activity in patients with resistant hypertension. However, its effect on systemic inflammation has not been examined. We prospective...

Full description

Saved in:
Bibliographic Details
Published in:Hypertension (Dallas, Tex. 1979) Tex. 1979), 2017-02, Vol.69 (2), p.323-331
Main Authors: Zaldivia, Maria T.K, Rivera, Jennifer, Hering, Dagmara, Marusic, Petra, Sata, Yusuke, Lim, Bock, Eikelis, Nina, Lee, Rebecca, Lambert, Gavin W, Esler, Murray D, Htun, Nay M, Duval, Jacqueline, Hammond, Louise, Eisenhardt, Steffen U, Flierl, Ulrike, Schlaich, Markus P, Peter, Karlheinz
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Aged, 80 and over
Blood Pressure - physiology
Blood Pressure Monitoring, Ambulatory
Catheter Ablation
Female
Flow Cytometry
Follow-Up Studies
Humans
Hypertension - blood
Hypertension - surgery
Kidney - innervation
Male
Middle Aged
Monocytes - metabolism
Platelet Aggregation - physiology
Prospective Studies
Sympathectomy - methods
Time Factors
Young Adult
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Overactivation of renal sympathetic nervous system and low-grade systemic inflammation are common features of hypertension. Renal denervation (RDN) reduces sympathetic activity in patients with resistant hypertension. However, its effect on systemic inflammation has not been examined. We prospectively investigated the effect of RDN on monocyte activation and inflammation in patients with uncontrolled hypertension scheduled for RDN. Ambulatory blood pressure, monocyte, and monocyte subset activation and inflammatory markers were assessed at baseline, 3 months, and 6 months after procedure in 42 patients. RDN significantly lowered blood pressure at 3 months (150.5±11.2/81.0±11.2 mm Hg to 144.7±11.8/77.9±11.0 mm Hg), which was sustained at 6 months (144.7±13.8/78.6±11.0 mm Hg). Activation status of monocytes significantly decreased at 3 months (P
ISSN:0194-911X
1524-4563
DOI:10.1161/HYPERTENSIONAHA.116.08373